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Abstract
Background: Platelet hyperaggregability is a pro-thrombotic feature of type-2 diabetes, associated with low levels
of the antioxidant glutathione (GSH). Clinical delivery of N-acetylcysteine (NAC), a biosynthetic precursor of GSH,
may help redress a GSH shortfall in platelets, thereby reducing thrombotic risk in type-2 diabetes patients. We
investigated the effect of NAC in vitro, at concentrations attainable with tolerable oral dosing, on platelet GSH
concentrations and aggregation propensity in blood from patients with type-2 diabetes.
Methods: Blood samples (n = 13) were incubated (2 h, 37°C) with NAC (10-100 micromolar) in vitro. Platelet
aggregation in response to thrombin and ADP (whole blood aggregometry) was assessed, together with platelet
GSH concentration (reduced and oxidized), antioxidant status, reactive oxygen species (ROS) generation, and
plasma NOx (a surrogate measure of platelet-derived nitric oxide; NO).
Results: At therapeutically relevant concentrations (10-100 micromolar), NAC increased intraplatelet GSH levels,
enhanced the antioxidant effects of platelets, and reduced ROS generation in blood from type-2 diabetes patients.
Critically, NAC inhibited thrombin- and ADP-induced platelet aggregation in vitro. Plasma NOx was enhanced by 30
micromolar NAC.
Conclusions: Our results suggest that NAC reduces thrombotic propensity in type-2 diabetes patients by
increasing platelet antioxidant status as a result of elevated GSH synthesis, thereby lowering platelet-derived ROS.
This may increase bioavailability of protective NO in a narrow therapeutic range. Therefore, NAC might represent
an alternative or additional therapy to aspirin that could reduce thrombotic risk in type-2 diabetes.
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Background
Oxidative stress is implicated in the aetiology and com-
plications of type-2 diabetes [1]. Elevated reactive oxy-
gen species (ROS) production is a feature of platelets in
type-2 diabetes [2] and contributes to hyperaggregability
associated with the disease [3,4] through both depres-
sion of intra-platelet antioxidant status and reduced
synthesis and bioavailability of anti-thrombotic nitric
oxide (NO) [5]. Oxidative stress also results in endothe-
lial dysfunction associated with atherosclerosis and sub-
sequent thrombotic complications [6], compounded in
type-2 diabetes by a sustained hypercoagulable state and
alterations in the fibrinolytic pathway. Since the revela-
tion that aspirin fails to show benefit in primary preven-
tion of cardiovascular events in diabetes [7,8], there is
renewed urgency in finding alternative antithrombotic
therapies.
Glutathione (GSH) is an abundant, key endogenous
antioxidant that is depressed in platelets from patients
with type-2 diabetes, contributing to hyperaggregability
[9]. Intramuscular GSH administration increases levels
of protective NO in platelets from type-2 diabetes
patients, with a concomitant decrease in plasma levels
of the fibrinolytic inhibitor, plasminogen activator inhi-
bitor-1 [10]. However, GSH is a poor candidate for oral
therapy on account of peptide digestion in the intestinal
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(NAC), on the other hand, is a well-recognised therapy
to redress acute GSH depletion in acetaminophen over-
dose. Therapeutic roles for NAC have also been pro-
posed in a range of clinical conditions, although there
are some doubts about its efficacy [11].
In the diabetes arena, oral NAC has been shown to
improve endothelial function in a rat model of diabetes
[12] and to reduce endothelial activation and oxidative
stress markers [13] and blood pressure [14] in patients
with type-2 diabetes. Very high concentrations (3 mmol/
l) augment NO-mediated inhibition of platelet aggrega-
tion in blood from obese patients in vitro [15]. Our own
study in vitro indicated that much lower concentrations
of NAC (10-100 μmol/l) depress platelet function in
blood from healthy volunteers, an effect that was asso-
ciated with increased intra-platelet GSH and inhibition
of oxidative stress [16].
Here, we tested the hypothesis that NAC, at plasma
concentrations achievable through oral dosing, inhibits
platelet hyperaggregability in blood from patients with
type-2 diabetes, and set out to examine the biochemical
background to any beneficial effects observed.
Methods
Clinical Study Design and Population
Eligible subjects with type-2 diabetes were recruited
through local General Practitioners. At an initial screen-
ing visit, venous blood (9 ml) was collected from the
antecubital fossa into lithium heparin-containing tubes
(Sarstedt Ltd, Leicester, UK) to screen lipid and renal
status (Piccolo Lipid and Renal Panels, respectively;
Abaxis, Darmstadt, Germany), whilst a finger-prick sam-
ple was obtained for HbA1C determination (DCA 2000+
Analyser; Bayer, Newbury, UK).
Subjects that met the inclusion criteria for the study
(Table 1) returned to the Highland Clinical Research
Facility within two weeks of the screening visit. Venous
blood (250 ml) was drawn from the antecubital fossa
using an intravenous cannula (BD Venflon 18G, BD
Medical, Oxford, UK) and transferred into tubes con-
taining 3.8% trisodium citrate or 7.5 g/l K3EDTA. Blood
cell counts (Beckman Coulter ACT10; Beckman Coulter,
High Wycombe, UK) were conducted on the trisodium
citrate sample, in triplicate, primarily in order to assess
platelet number in the samples used for aggregometry
and biochemical assays.
O ns t u d yd a y s ,f o l l o w i n ga1 2hf a s t ,v o l u n t e e r s
arrived at the Highland Clinical Research Facility
(between 9-10 am to minimise diurnal variation of anti-
oxidant levels and blood constituents, particularly plate-
lets). All subjects provided informed written consent
prior to participation. The study was approved by the
Highland Research Ethics Committee and was con-
ducted in accordance with the Declaration of Helsinki
and its amendments.
Statistical Power
A review of the literature pertaining to the various
assays conducted in this project identified platelet aggre-
gometry (thrombin agonist) as the least powerful techni-
que. For a significance level of 5% and a power of 80%
for detecting a change in aggregation of 30%, 15 subjects
were recruited. Complete data sets were achieved for n
= 13 (aggregometry) and n = 10-12 for biochemical
measures.
Blood Preparation
Citrated blood samples were divided into four groups: a
control with no NAC, and three treatment groups (10,
30 and 100 μmol/l NAC). Blood samples were incubated
with NAC (or vehicle control) for 2 h at 37°C.
Washed platelet preparation
Platelet rich plasma (PRP) was first prepared from
citrated whole blood by centrifugation (200 g, 10 min,
room temperature). Platelets were washed by centrifu-
ging (1200 g, 10 min, room temperature) 2 ml PRP ali-
quots treated with prostacyclin (PGI2; 30 ng/ml). The
plasma was subsequently aspirated and replaced with an
equal volume of citrated (3.8% trisodium citrate) Tyrode
buffer (composition in mmol/l: 137 NaCl, 2.7 KCl, 1.05
MgSO4,0 . 4N a H 2PO4,1 2 . 5N a H C O 3,5 . 6G l u c o s e ,1 0
HEPES and 0.8 CaCl2;p H7 . 4 )c o n t a i n i n g3 0n g / m l
PGI2, prior to gentle resuspension of the platelets with
the aid if a micropestle. Following a second centrifuga-
tion and aspiration of the supernatant, the platelets were
gently resuspended in Tyrode buffer in the absence of
PGI2. Platelet preparations were standardized to 100 ×
Table 1 Patient characteristics
Parameter
Age (years) 59.2 ± 3.7
Gender (M:F) 10:5
BMI (kg/m
2) 32.2 ± 1.9
HbA1C (%) 6.5 ± 0.3
Total Cholesterol (mmol/l) 4.4 ± 0.2
LDL Cholesterol (mmol/l) 2.5 ± 0.1
HDL Cholesterol (mmol/l)* 1.4 ± 0.1
Triglycerides (mmol/l) 1.3 ± 0.1
Creatinine (μmol/l) 91.5 ± 6.5
Fasting glucose (mmol/l) 7.9 ± 0.5
Haemoglobin (g/l) 117 ± 5.0
Haematocrit (%) 37.1 ± 1.4
Platelets (× 10
9 cells/l) 208.1 ± 16.1
Abbrevations: *, calculated; BMI, body mass index; F, female; HbA1C,
glycosylated haemoglobin; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; M, male. Data are expressed as mean ± sem (n = 15).
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9 platelets/l using citrated Tyrode buffer for use in all
experiments requiring washed platelets.
Platelet Aggregation
Platelet aggregation was assessed in a 4-channel impe-
dance aggregometer (Chrono-Log Model 700 Lumi-
Aggregometer; LabMedics, Manchester, United King-
dom). Diluted blood (500 μl whole blood + 500 μl0 . 9 %
saline) was pre-warmed at 37°C for 5 min. Aggregation
was initiated by addition of ADP (Labmedics, Manche-
ster, UK; 0.625 - 10 μmol/l) or thrombin (0.125 - 1 U/
ml) and progress tracked as the area subtended by the
resultant increase in impedance over 6 min. Experi-
ments were conducted at 37°C with a stirring speed of
1000 rpm and impedance gain of 0.05. No specific antic-
oagulant was added to the thrombin-treated prepara-
tions in order to preserve the full pharmacological
impact of thrombin in these experiments; the aggrega-
tory response to thrombin is strictly a combination of
platelet and coagulation cascade activation.
Glutathione (GSH) Determination
Total GSH (i.e. GSH+GSSG) and GSSG levels were
measured in platelet extracts using the GSH reductase
enzyme method; the protocol is described in fine detail
in a previous publication [17]. This assay involves the
thiol-mediated conversion of 5,5’-dithio-bis (2 nitroben-
zoic acid) (DTNB; Ellman’s reagent) to 5-thio-2-nitro-
benzoic acid (TNB), detectable at l = 412 nm. The test
is specific to GSH on the basis of the specificity of the
GSH reductase enzyme to GSH: the rate of accumula-
tion of TNB is proportional to the concentration of
GSH in the sample. Briefly, platelets from untreated and
NAC-treated (2 h, 37°C) blood samples (collected in
EDTA) were isolated by centrifugation (200 g; 10 min)
to obtain PRP, prior to further centrifugation steps (2 ×
>1 2 0 0g, 4°C, 10 min) to first isolate and then wash the
platelet pellet. Supernatant was then removed and the
platelet pellet exposed to metaphosphoric acid (5%; 4°
C). After centrifugation, the cell lysate was collected and
diluted 1:1 with KPE buffer prior to addition of freshly
prepared DTNB and GSH reductase solutions, prepared
according to [17]. Following addition of b-NADPH, the
absorbance (l = 412 nm) was measured immediately
a n da t3 0si n t e r v a l sf o r2m i ni na9 6w e l lp l a t e .T h e
rate of change in absorbance was compared to that for
GSH standards. The method for assessment of the
GSSG in each sample was identical to that for GSH, but
with a prior treatment of the sample with 2-vinylpyri-
dine to react out the reduced GSH at the outset. Protein
concentrations in extracts were quantified (Coomassie
Protein Assay Kit, Perbio Science UK Ltd, Northumber-
land, UK).
Platelet EPR Spectrometry
EPR is a specific technique to enable the measurement
of free radicals: only entities with unpaired electrons are
detected by the technique. The highly reactive nature of
oxygen-centred free radicals (e.g. superoxide and hydro-
xyl) means that they do not exist sufficiently long in
samples to be measured directly. Instead, high concen-
trations of a suitable ‘spin-trap’ are used to compete
with other potential reactants for free radicals: the pro-
duct of the reaction of a radical with such a trap forms
a stable radical (spin-adduct) that is detectable by EPR
spectrometry. The intensity of the signal increases as
the spin-adduct accumulates at a rate that is propor-
tional to the rate of free radical production.
Potential antioxidant effects of washed platelets were
assessed using an in vitro model of oxidative stress. The
foundation for the model is that HEPES present in Tyr-
ode buffer is known to spontaneously generate oxygen-
centred radicals [18] that are detectable using the cell-
permeable spin trap that is specific for oxygen-centred
radicals (1-hydroxy-3-carboxy-pyrrolidine, CP-H;
Axxora, Nottingham, UK). Briefly, whole blood was
incubated (2 h; 37°C) with NAC (10-100 μmol/l) as
described above, prior to preparation of washed platelets
from the samples (washing removes extracellular NAC
and facilitates introduction of radical-generating HEPES
in Tyrode buffer). 1 mmol/l CP-H spin-trap was then
added to the washed platelets and the EPR signal corre-
sponding to the spin adduct CP
., was measured at 30
min intervals for a further 4 h using EPR spectrometry
(Miniscope MS200; Magnettech, Germany; parameter
settings: B0-field, 3356 G; sweep width, 50 G; sweep
time, 30 s; modulation amplitude, 1500 mG; microwave
power, 20 mW; microwave frequency, 9.3 GHz; gain, 1).
The ability of platelets pre-treated with NAC to effec-
tively compete with the spin trap for oxygen-centred
free radicals was assessed by comparison to an untreated
control washed platelet preparation and to Tyrode buf-
fer without platelets for each of 12 patient samples.
ROS Generation: Chemiluminescence
Generation of ROS was determined using lucigenin-
derived chemiluminescence in washed platelets. Washed
platelets were incubated for 10 min in a Lumi-Aggreg-
ometer (Chrono-Log Model 700 Lumi-Aggregometer,
LabMedics, Manchester, UK; settings: 37°C; stirring
speed 1000 rpm; luminescence gain 2). Lucigenin (125
μmol/l), a luminescent probe for detecting ROS, was
incubated with samples for 10 min - the area under the
curve for the luminescent signal generated corresponded
to the basal level of ROS in each sample. Subsequently,
thrombin (1 U/ml) was added to stimulate the ROS
release and the chemiluminescent signal quantified over
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added to verify the sensitivity of the assay for detecting
O2
.-.
Platelet NO Synthase (NOS)-derived NO metabolites (NOx)
Measurement of NO metabolites (NOx) in collagen-acti-
v a t e dw a s h e dp l a t e l e t sw a su s e da sas u r r o g a t em a r k e r
of platelet NOS activity [19]. NO has a half-life of sec-
onds in biological media, making it extremely difficult
to measure. The major product of NO oxidation/meta-
bolism is nitrite (NO2
-), which can further oxidise to
nitrate in a process that is accelerated by iron centres
(e.g. haem). Other potential fates of NO are peroxyni-
trite (ONOO
-), which would be expected to isomerise to
nitrate or react to form other products (e.g. nitrotyro-
sine) and S-nitrosothiols. The assay used in this study
does not detect nitrate, but does not discriminate
between NO2
- and S-nitrosothiols (collectively termed
NOx from now on). Briefly, samples of treated (NAC;
10-100 μmol/l; 2 h; 37°C) and untreated citrated whole
blood were centrifuged, the platelet rich plasma aspi-
rated and washed, as described above. Samples were
then divided into two: half was treated with the NOS
inhibitor, L-NAME (200 μmol/l; 37°C), for 10 min,
whilst the other half remained untreated. Samples were
activated with collagen (2 μg/ml; Labmedics, Manche-
ster, UK) and incubated (5 min; 37°C) and snap-frozen.
Thawed samples (100 μl) were injected into a purge ves-
sel containing glacial acetic acid and potassium iodide;
NO generated in the purge vessel was transferred in a
carrier gas (oxygen-free nitrogen) to a chemilumines-
cence NO Analyser (Sievers 280i NO analyzer; GE Ana-
lytical Instruments, Colorado, USA; method of [20]).
The difference in NOx detected in the L-NAME-treated
and untreated portions for each sample were taken to
represent platelet NOS-derived NOx.
NAC measurement
Total NAC (i.e. oxidized + reduced) was measured in
platelet extracts using HPLC with fluorescence detection
(Agilent Technologies 1200 Series, South Queensferry,
UK) - adapted from [21].
Statistical Analyses
Results are expressed as mean ± sem. Concentration-
response curves were fitted to non-linear regression (sig-
moidal dose-response, variable slope), except for calibra-
tion curves which were fitted to linear regression. Curve
fitting and statistical tests were performed using Graph-
Pad Prism software (version 5.00). Data distribution was
assessed using the Kolmogorov-Smirnov test. All data
sets followed Gaussian distribution; it was therefore
appropriate to use one-way ANOVA to compare more
than two groups and one factor. Concentration-response
curves were analysed by two-way ANOVA with repeated
measures. Dunnett’s or Bonferroni post hoc tests were
conducted, where appropriate, to correct for multiple
testing. P < 0.05 was considered to be statistically
significant.
Drugs, Chemicals, Reagents and Other Materials
All drugs were obtained from Sigma (Poole, UK) unless
otherwise specified. The spin adduct, 4-oxo-tempo, and
spin trap, CP-H, were constituted using phosphate-buf-
fered saline; CP-H also contained EDTA (10 mmol/l
final concentration).
Results
Subject Characteristics
The characteristics of the study population are shown in
Table 1.
Therapeutic Potential of NAC to Reduce Platelet
Hyperaggregability
Thrombin and ADP both induced aggregation in diluted
whole blood preparations, although the maximum
aggregation was much greater in thrombin-treated pre-
parations than those exposed to ADP. All three concen-
trations of NAC (10-100 μ mol/l; 2 h incubation) caused
inhibition of thrombin (P < 0.01 for 10 μ mol/l NAC, P
< 0.001 for 30 and 100 μ mol/l compared to control;
two-way ANOVA,) and ADP (P < 0.001 for all NAC
concentrations compared to control; two-way ANOVA)
-induced platelet aggregation in whole blood from
patients with type-2 diabetes (Figure 1A and 1B). Blood
from all patients (n =1 3 )r e s p o n d e dt oN A C .T h ec o n -
centration-dependent effects of NAC on inhibiting pla-
telet aggregation were particularly marked for thrombin-
induced aggregation (Figure 1A).
Glutathione Status
NAC increased total GSH concentration in a concentra-
tion-dependent manner (P < 0.0001; Figure 2A), but did
not impact on GSSG levels (P = 0.52; Figure 2B).
Antioxidant Effect of Washed Platelets
Washed platelets with no treatment had an antioxidant
effect (P = 0.01) in most type-2 diabetes patients (n =
12). However, washed platelets from a patient subset (n
= 3) displayed a higher EPR signal intensity than the
control (Tyrode buffer), indicating a pro-oxidant activity.
Nevertheless, treatment with NAC was increased the
antioxidant effect of washed platelets (P < 0.0001; Figure
3A) in blood from all patients, most markedly with 30 μ
mol/l NAC. Following two cycles of platelet washing,
NAC was undetectable in the plasma or in platelet
extracts (via fluorescence HPLC, detection threshold ~2
μmol/l). Typical EPR spectra are illustrated in Figure 3B.
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In both non-activated (basal) and thrombin (1 U/ml)-
activated platelets (washed preparation), ROS generation
was inhibited in a concentration-dependent manner by
NAC (P < 0.0001; Figure 3C). Activation with thrombin
increased ROS generation relative to the corresponding
basal levels (P < 0.0001). The addition of SOD (300 U/
ml; n = 6) abolished the luminescence signal (P <
0.0001; data not shown).
Platelet NO Bioavailability
Incubation (2 h, 37°C) with 30 μmol/l NAC increased L-
NAME-sensitive NOx levels (×2.6 compared to control;
p < 0.05; Figure 3D). The impact of 10 and 100 μmol/l
NAC on platelet NOx did not reach statistical
significance.
Discussion
This study shows that NAC, at appropriate plasma con-
centrations for realistic oral dosing [22], inhibits throm-
bin- and ADP-induced platelet aggregation in blood
from patients with type-2 diabetes. This anti-platelet
effect is associated with increased intra-platelet GSH
and enhanced antioxidant activity. Moreover, ROS gen-
eration from both activated and quiescent platelets
decreased with NAC supplementation. Finally,
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Figure 1 Therapeutic potential of in vitro additions of NAC to
reduce platelet aggregability in whole blood from patients
with type-2 diabetes. Inhibition of (A) thrombin- (0.125-1.0 U/ml)
and (B) ADP (10 μmol/l)-induced platelet aggregation, by NAC (10-
100 μmol/l; 2 h, 37°C), (n = 13 for both). Black circles = vehicle
control; white triangles = 10 μmol/l NAC; black squares = 30 μmol/l
NAC; white diamonds = 100 μmol/l NAC. Data are expressed as
mean ± sem; statistical analysis was performed by two-way ANOVA
with Bonferroni’s post hoc correction for multiple testing (treatment
vs control). **P < 0.01, ***P < 0.001.
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Figure 2 NAC impact on (A) total and (B) oxidised glutathione
in platelet extracts (n = 11). Data are expressed as mean ± sem;
statistical analysis was performed by one-way ANOVA with
Dunnett’s post hoc test vs control. *P < 0.05; ***P < 0.001.
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bioavailability, was increased by 30 μmol/l NAC. Over-
all, our findings suggest that NAC inhibits platelet
hyperaggregability in blood from patients with type-2
diabetes by reversing oxidative stress and increasing
antioxidant capacity via increased GSH biosynthesis.
The NAC concentrations chosen for this study
approximate the peak plasma concentrations achievable
with oral doses of 100-1000 mg [22]. The duration of
drug exposure in vitro was a compromise between the
likely peak effect of NAC on intracellular GSH [22] and
the maximum period for maintenance of optimal plate-
let function after sampling (3 h).
In blood from all type-2 diabetes patients studied (n =
13), platelet aggregation was inhibited significantly by
NAC at all three concentrations, irrespective of whether
thrombin (which activates both platelet aggregation and
coagulation) or ADP (a specific platelet activator) was
the agonist involved. The results are similar in nature (if
not mechanism) to those reported for high concentra-
tion, short duration exposure to NAC of platelets from
obese subjects [15]. In addition, our findings are in
accordance with those reported previously in platelets
from healthy volunteers [16], although the effect is more
dramatic and displays a greater concentration depen-
dence in platelets from the type-2 diabetes patient
group compared to controls. Nevertheless, there results
suggest a levelling-off of the effect at 100 μmol/l, per-
haps suggesting that higher concentrations might not
continue to further suppress aggregation.
The suppressed aggregation of platelets treated with
NAC was associated with an increase in their capacity
to deal with oxidative stress, manifested as lowered ROS
production. The fact that SOD abolished the lumines-
cence signal indicates that the majority, if not all, of the
ROS detected was
.O2
-.T h i sa g r e e sw i t hp r e v i o u ss t u -
dies highlighting the significance of
.O2
- in altering pla-
telet function [5].
Importantly, the depression in ROS generation is not a
direct action of NAC, which we showed previously to be
a weak antioxidant in its own right [16]. Indeed, these
assays were performed only after two platelet washing
cycles to ensure removal of extracellular NAC, and
HPLC measures on treated platelet extracts failed to
detect intra-platelet NAC (detection threshold ~2 μmol/
l). Instead, we surmise that the antioxidant effect of
NAC is primarily mediated through its ability, as a bio-
synthetic precursor, to boost production of intra-platelet
GSH, consistent with previous studies in other cell types
(for example [23]).
It is perhaps surprising that an acute normalization of
the intra-platelet redox-environment should have such
rapid effects with respect to reducing platelet aggregabil-
ity, because much of the oxidative damage caused by
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Figure 3 Effect of in vitro additions of NAC on antioxidant
capacity and platelet-derived ROS in platelet samples from
patients with type-2 diabetes.( A) Mean data for the effect (n =
12); data are expressed as mean ± sem; statistical analysis was
performed by one-way ANOVA with Dunnett’s post hoc test vs
control. **P < 0.01; ***P < 0.001. (B) Typical 3-line EPR spectra
obtained at the 4 h reading for Tyrode’s buffer alone and in washed
platelets with or without treatment with NAC (10-100 μmol/l; 2 h;
37°C - NAC washed out of supernatant before addition of spin-trap).
(C) ROS detection in washed platelets. Luminescence detection of
ROS in both the basal state (black bars) and following thrombin-
stimulation (white bars) of washed platelets (n = 12). Data are
expressed as mean ± sem; statistical analysis was performed by
one-way ANOVA with Dunnett’s post hoc test vs control for each
group (basal and thrombin-activated samples were analysed
separately). **P < 0.01; ***P < 0.001 (thrombin-activated vs control):
#P < 0.05;
###P < 0.001 (basal vs control). (D) L-NAME sensitive nitrite
detection in collagen activated washed platelets (n = 10). Data are
expressed as mean ± sem; statistical analysis was performed by
one-way ANOVA with Dunnett’s post hoc test vs control. **P < 0.01.
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would take much longer to reverse. However, the intra-
platelet, constitutive NO synthase (NOS)-mediated
synthesis of NO responds rapidly to changes in Ca
2+
produced by platelet activation. It has been postulated
that release of NO upon platelet activation acts as a
negative feedback to further platelet activation/recuit-
ment, thereby raising the threshold of stimulus neces-
sary to cause aggregation, and helping to prevent
inappropriate thrombus formation. It follows that loss of
NO, through quenching by ROS, could release this phy-
siological brake, thereby encouraging aggregation. Given
that the interaction between ROS and NO is very rapid,
an increase in the antioxidant capacity within platelets
would have an immediate impact on NO bioavailability.
Our experiments to measure exclusively NOS-derived
NOx in activated platelet preparations indicated that the
intermediate concentration of NAC (30 μmol/l)
increased NOS-dependent NOx formation by ~2.5-fold.
A similar increase in NO bioavailability with NAC was
reported in a previous study [14], in which the authors
suggested that the effect was due to increased NO
synthesis. We make no such assertion, because NO
bioavailability is affected by the rates of both NO synth-
esis (via NOS) and inactivation, particularly by oxygen-
centred free radicals like
.O2
-. Interestingly, in our
experiments, the effect was only seen at 30 μmol/l NAC;
it was not matched in samples treated with either 10 or
100 μmol/l NAC, perhaps suggesting a very narrow
therapeutic window for this action. In light of these
results, we speculate that continuing to increase NAC in
an effort to improve efficacy might prove counter-
productive.
Whilst the GSH-dependent antioxidant hypothesis
might go some way to explain the inhibitory effect of
NAC in this study, the lack of consistent concentration-
dependence between the various measures (ROS genera-
tion, platelet antioxidant activity, GSH levels, NOS-
dependent NOx) suggests that the antioxidant activity,
which is apparently saturated by ~30 μmol/l, is supple-
mented by alternative mechanisms of action at higher
concentrations. One possible explanation is that NAC
may be having direct effects at the receptor level in pla-
telets, as seen in similar studies using human macro-
phages and vascular smooth muscle cells [24,25].
Conclusions
NAC, at pharmacologically-relevant concentrations, sig-
nificantly inhibits platelet hyperaggregability in type-2
diabetes patients in vitro. The likely mechanism is
through enhancement of platelet GSH levels, suppres-
sion of ROS and, possibly, increased protection of the
anti-aggregation local messenger, NO. This study dis-
plays the clinical potential of NAC in treating platelet
hyperaggregability in type-2 diabetes. Moreover, in view
of both the ineffectiveness of aspirin in this patient
group [7,8], and recent findings relating to a protective
role for NAC in hypertension and endothelial function
[13,14], a clinical trial of oral NAC in a type-2 diabetes
context is justified.
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